The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

The FDA's expanded approval will allow the drug to be more accessible with insurance. Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

The Qatar Financial Centre (QFC) has reported "exceptional" growth with combined assets under management of more than $33bn in 2024 as total number of registered firms stood at 2,489. The firms ...

Doha – Qatar: Qatar Financial Centre (QFC), a leading onshore financial and business hub in the region, witnessed record growth in 2024, welcoming 836 new firms to its platform, a 156 per cent growth ...